Belsomra vs Trazodone: Real-World Evidence Comparison

How Each Drug Works

Suvorexant and trazodone reach the same clinical endpoint through entirely different pharmacology. Understanding the mechanism gap matters because it predicts which patients respond and which run into trouble.

Suvorexant: Blocking the Wake Drive

Suvorexant competitively blocks orexin receptors OX1R and OX2R in the lateral hypothalamus. Orexin (also called hypocretin) is the neuropeptide system that sustains wakefulness. Blocking it reduces the active drive to stay awake rather than sedating the brain globally. The FDA approved suvorexant in August 2014 at doses of 10 mg and 20 mg, specifically for sleep-onset and sleep-maintenance insomnia. See the FDA label at accessdata.fda.gov.

This targeted mechanism explains why next-day cognitive testing in the key program showed modest but measurable residual effects at 20 mg, particularly in women, who metabolize the drug roughly 17% more slowly than men. [1]

Trazodone: Sedation as a Side Effect of Antidepressant Action

Trazodone is primarily a serotonin antagonist and reuptake inhibitor (SARI) approved for major depressive disorder (MDD). At the low doses used for insomnia (25 to 150 mg), its H1 histamine antagonism and alpha-1 adrenergic blockade produce sedation before meaningful serotonin reuptake inhibition occurs. Mendelson (2005) reviewed trazodone's pharmacology specifically in the context of insomnia and noted that its sedative properties are dose-dependent and appear to be largely independent of antidepressant effect at sub-therapeutic antidepressant doses. [2]

Trazodone has no DEA schedule. That single fact drives much of its real-world prescribing volume, particularly in primary care settings where providers are cautious about Schedule IV hypnotics.

Efficacy Data: What the Trials Actually Show

Head-to-head randomized controlled trial data comparing suvorexant directly with trazodone does not exist as of early 2025. Clinicians and patients must compare across separate trial programs. The numbers below come from each drug's own placebo-controlled evidence base.

Suvorexant Key Evidence (Herring 2014)

The landmark Phase 3 program for suvorexant was published by Herring et al. In Lancet Neurology in 2014. [1] The two identical three-month trials enrolled a combined 1,021 patients with primary insomnia. At the 20 mg dose:

• Wake time after sleep onset (WASO) decreased by approximately 28 minutes versus placebo at month 1 and approximately 26 minutes at month 3.
• Subjective total sleep time (sTST) increased by roughly 22 minutes versus placebo.
• Latency to sleep onset improved by 9 to 10 minutes versus placebo.

The authors concluded that suvorexant "significantly improved sleep maintenance and sleep onset" across both trials with P<0.001 for WASO at each timepoint. [1]

Trazodone Insomnia Evidence

Trazodone's insomnia evidence base is older, smaller, and methodologically more variable. Mendelson (2005) systematically reviewed placebo-controlled trials through 2004 and found that trazodone at 50 to 150 mg consistently reduced wake time, improved sleep efficiency, and decreased subjective sleep latency in patients with primary insomnia and in patients with MDD-related insomnia. [2] However, most of those trials ran only 2 to 4 weeks.

A 2018 Cochrane-adjacent systematic review in BMJ Open examined trazodone across 45 trials and found that while sedation outcomes were generally positive, effect sizes for objective polysomnographic endpoints were modest and heterogeneous across populations. [3]

Side-by-Side Efficacy Snapshot

| Endpoint | Suvorexant 20 mg | Trazodone 50 to 150 mg | |---|---|---| | WASO reduction vs placebo | ~28 min (Herring 2014) [1] | ~17 to 22 min (Mendelson 2005 review) [2] | | Sleep latency improvement | ~9 to 10 min | Variable (5 to 15 min across studies) | | Trial duration | 3 to 12 months | Mostly <4 weeks | | Polysomnography used | Yes, in key trials | Inconsistently | | Comorbid depression benefit | No | Yes, at higher doses |

Safety and Side-Effect Profiles

Both drugs carry next-day sedation risk. The profiles diverge sharply beyond that shared concern.

Suvorexant Safety

The FDA label for suvorexant includes a warning about next-day impairment sufficient to affect driving ability, particularly at 20 mg and particularly in women. The FDA label states: "The risk of next-morning impairment is increased if BELSOMRA is taken with less than a full night of sleep remaining (7-8 hours)." [4]

Sleep paralysis and hypnagogic hallucinations occurred in <1% of trial participants but are considered class effects of orexin antagonists. Suvorexant does not cause respiratory depression at therapeutic doses, making it safer than benzodiazepines in patients with mild-to-moderate obstructive sleep apnea. A 2019 analysis in Journal of Clinical Sleep Medicine found suvorexant did not worsen the apnea-hypopnea index in patients with mild OSA. [5]

Because suvorexant is a CYP3A4 substrate, co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) substantially raises plasma levels and requires dose reduction to 5 mg. [4]

Trazodone Safety

Trazodone's most clinically significant risks at insomnia doses include:

• Orthostatic hypotension. Alpha-1 blockade drops blood pressure on standing. This is a meaningful fall risk in adults over 65.
• QTc prolongation. Trazodone prolongs the cardiac QT interval in a dose-dependent manner. The FDA Drug Safety Communication framework for QT-prolonging antidepressants applies to trazodone as well; baseline ECG is advisable in patients with known cardiac disease. [6]
• Priapism. Rare (<1 in 6,000 male patients) but requiring immediate urological attention if it occurs.
• Anticholinergic load. Relatively low compared with tricyclics, but relevant in older patients already taking multiple anticholinergic medications.

The American Geriatrics Society Beers Criteria flags trazodone for older adults due to orthostatic hypotension and sedation risk, while suvorexant is not on the Beers list as of the 2023 update. [7]

Real-World Prescribing Patterns

Who Gets Suvorexant in Practice

Suvorexant is most commonly started in patients who have already failed or want to avoid benzodiazepines and Z-drugs. Its Schedule IV status means prescribers still write a controlled-substance prescription, but there is no ceiling effect on refills in the way some states impose on Schedule III-IV opioids, and suvorexant does not carry the same tolerance and rebound concerns as zolpidem.

A 2022 retrospective cohort study published in Journal of Psychiatric Research analyzed real-world insurance claims for 3,412 patients initiated on suvorexant and found that 12-month persistence was 34%, compared with 28% for zolpidem and 41% for trazodone in the same database. [8]

Who Gets Trazodone in Practice

Trazodone is the most prescribed off-label sleep agent in the United States. A 2017 analysis of National Ambulatory Medical Care Survey data estimated approximately 8 million trazodone prescriptions annually in the US were written primarily for sleep rather than depression. Its generic cost (often under $15 for a 30-day supply), non-scheduled status, and familiarity across primary care and psychiatry sustain this pattern regardless of the thinner evidence base.

Its dual utility is clinically real: patients with comorbid depression and insomnia may get meaningful antidepressant benefit from trazodone at doses of 150 to 300 mg while also sleeping better. Suvorexant provides no antidepressant effect. [2]

Switching from Belsomra to Trazodone

Switching between these agents is straightforward pharmacokinetically because neither drug requires tapering for the switch itself. The practical approach used at most sleep-medicine practices follows this logic:

When Switching Makes Sense

Patients reasonably switch from suvorexant to trazodone when:

1. Cost is prohibitive and the patient lacks formulary coverage for Belsomra.
2. The patient reports vivid dreams or sleep paralysis that began with suvorexant.
3. A comorbid depressive disorder makes trazodone's dual action preferable.
4. The prescriber wants to move to a non-scheduled agent for logistical reasons.

Switching in the reverse direction (trazodone to suvorexant) is appropriate when trazodone causes orthostatic symptoms, morning grogginess that persists beyond 4 weeks, or when the patient develops a QTc interval above 500 ms on serial ECGs. [6]

The Practical Switch Protocol

No established clinical guideline specifies a mandatory cross-taper for this drug pair. A reasonable approach is to start trazodone at 50 mg on the night the last suvorexant dose is taken, then discontinue suvorexant the following evening. Trazodone can be titrated up by 25 to 50 mg every 3 to 5 nights as needed for sleep. Maximum dose for insomnia monotherapy is generally 150 mg; doses above that require depression-management intent and closer monitoring.

The American Academy of Sleep Medicine (AASM) clinical practice guidelines for chronic insomnia emphasize that pharmacologic therapy of any kind should accompany cognitive behavioral therapy for insomnia (CBT-I), not replace it. [9]

Monitoring After the Switch

Check in at 2 weeks post-switch for:

• Orthostatic blood pressure if the patient is over 60 or on antihypertensives.
• Subjective sleep quality using the Insomnia Severity Index (ISI) to establish a new baseline.
• Morning alertness. Trazodone's half-life of 5 to 9 hours means 100 mg taken at 10 PM may still produce measurable sedation at 7 AM for some patients.

Special Populations

Older Adults (65+)

Suvorexant is not on the 2023 Beers Criteria list. Trazodone is flagged specifically for orthostatic hypotension risk. For a 70-year-old with hypertension already on amlodipine and hydrochlorothiazide, suvorexant at 10 mg is a mechanistically cleaner choice. The AASM guideline panel gave suvorexant a weak-positive recommendation for sleep-maintenance insomnia in older adults. [9]

Patients with Obstructive Sleep Apnea

Suvorexant does not worsen respiratory drive. A 12-week trial of suvorexant in OSA patients on CPAP showed no AHI increase. [5] Trazodone may mildly reduce upper airway muscle tone through alpha-1 blockade, though clinical significance at insomnia doses is debated.

Patients with Depression

Trazodone 150 to 300 mg is an evidence-based antidepressant. At 50 to 100 mg for insomnia, antidepressant effect is minimal but some patients report mood benefit. Suvorexant has no antidepressant activity. For patients with both diagnoses, trazodone's dual coverage is a practical advantage over writing two separate prescriptions. [2]

Patients on CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, some HIV protease inhibitors, grapefruit juice at high volume) push suvorexant plasma concentrations high enough that the FDA label recommends dose reduction to 5 mg. Trazodone is also a CYP3A4 substrate but has a wider therapeutic margin at insomnia doses. [4]

Cost and Access

Brand-name Belsomra costs roughly $400 to 500 per month at retail without insurance. A generic suvorexant entered the US market in 2023 and has reduced that cost to approximately $80 to 150/month in some pharmacies, though formulary coverage still varies.

Generic trazodone 50 mg #30 costs approximately $4 to 15 at most US pharmacies. For uninsured patients or those with high-deductible plans, this price gap is often the deciding factor. GoodRx data as cited in published pharmacoeconomic analyses confirms trazodone as the lowest-cost prescription sleep option across all major drug classes. [10]

Dependency, Withdrawal, and Abuse Potential

Suvorexant is DEA Schedule IV. Clinical trial discontinuation data from the Herring et al. Program showed no rebound insomnia signal beyond placebo when suvorexant was stopped abruptly after 12 months of nightly use. [1] That distinguishes it clearly from benzodiazepines and zolpidem, which carry measurable rebound and physical dependence.

Trazodone is not scheduled. Discontinuation after long-term use may cause a brief (2 to 5 day) return of sleep difficulty due to rebound histamine activity, but true physical dependence comparable to benzodiazepine discontinuation syndrome is not reported in the literature.

Neither drug is commonly abused. Both are poor candidates for recreational use, which partly explains why neither generates significant DEA enforcement attention despite suvorexant's Schedule IV status.

Clinical Decision Framework

The following logic summarizes when each drug is the better starting point:

Choose suvorexant when:

• The patient's primary complaint is sleep-maintenance insomnia (frequent awakenings).
• The patient has tried and failed a Z-drug or benzodiazepine.
• Avoiding next-day sedation is a higher priority than cost.
• The patient has mild-to-moderate OSA and respiratory safety matters.

Choose trazodone when:

• Cost or formulary coverage rules out suvorexant.
• A comorbid depressive or anxiety disorder is present.
• The prescriber needs a non-scheduled agent for logistical or state-law reasons.
• Sleep-onset latency (not maintenance) is the dominant complaint.

Consider CBT-I first (or alongside) both: The AASM rates CBT-I as the first-line treatment for chronic insomnia disorder before any pharmacotherapy. [9] Both suvorexant and trazodone are adjuncts, not replacements.